39 completed, 6 unknown, 3 withdrawn, 2 recruiting. 20 Not applicable, 10 Phase 2, 8 Phase 3, 4 Phase 4, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 20 | Completed 15, Unknown 4, Recruiting 1 |
| Phase 2 | 10 | Completed 6, Withdrawn 3, Terminated 1 |
| Phase 3 | 8 | Completed 6, Unknown 2 |
| Phase 4 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
Follow Vulvovaginal Atrophy: new trials by email Literature Review of Vulvovaginal Atrophy trials Research Report on Vulvovaginal Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Determining the Extent of the Genitourinary Syndrome of Menopause Burden in Breast Cancer Survivors Questionnaires (NRS, DASS-21, EORTC QLQ-C30, EORTC QLQ-BR42, FSFI, FSDS-R) - Genitourinary Syndrome of Menopause (GSM), Breast Cancer | Recruiting | Jessa Hospital | 264 | 2026-03-05 | 2026-05-04 | |
| Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients GynWave-360, Local hydratation - Vaginal Dryness, Breast Cancer | Not applicable | Recruiting | Centre Oscar Lambret | 75 | 2025-06-12 | 2026-03-18 |
| A Comparison of Hyaluronic Acid and Estradiol Treatment in Vulvovaginal Atrophy. Hyaluronic acid vaginal gel, Estrogen vaginal use form - Vulvovaginal Atrophy | Not applicable | Completed | Koru Health Groups | 300 | 2023-04-05 | 2023-11-22 |
| Combination of BTL-785F and HPM-6000UF Devices for Women's Intimate Wellness Treatment with BTL-785F and HPM-6000UF Devices - Vulvovaginal Atrophy, Urinary Incontinence | Not applicable | Completed | BTL Industries Ltd. | 25 | 2023-02-20 | 2025-02-26 |
| Psychometric Validation of the Portuguese DIVAS-Q in Women With Vulvovaginal Atrophic Symptoms Vulvovaginal Atrophy, Genital Disorder | Completed | Instituto Politécnico de Leiria | 300 | 2022-10-02 | 2026-05-19 | |
| Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM Vulvovaginal Atrophy, Menopause | Completed | Massachusetts General Hospital | 210 | 2022-09-01 | 2025-05-30 | |
| Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women IVR Dose 1, IVR Dose 2 - Vulvovaginal Atrophy, Vasomotor Symptoms | Phase 1 / Phase 2 | Completed | Daré Bioscience, Inc. | 21 | 2022-04-11 | 2024-10-31 |
| GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy. Estrogen, dehydroepiandrosterone, Estrogen + probiotics - Vulvovaginal Atrophy, Breast Cancer | Phase 4 | Completed | University Hospital, Ghent | 31 | 2022-03-21 | 2026-08-13 |
| Non-hormonal Medical Device for Treatment of Vulvovaginal Atrophy (VVA) in Post-Menopausal Women Non-hormonal vaginal device therapy, Sham vaginal device therapy - Vulvovaginal Atrophy | Not applicable | Completed | Madorra | 25 | 2021-07-09 | 2023-01-13 |
| Effects of Visnadin, Ethyl Ximeninate, Coleus Barbatus and Millet in Emulgel on Sexual Function in Postmenopausal Women Visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel, Emulgel-only - Female Sexual Function, Vulvovaginal Atrophy | Not applicable | Unknown | Chulalongkorn University | 100 | 2021-05-27 | 2024-03-22 |
| Clinical Study to Evaluate the Efficacy of Prasterone Treatment for Atrophy Vulvovaginal in Postmenopausal Women With Vulvar / Vestibular Pain Prasterone 6.5 MG, Placebo - Vulvovaginal Atrophy | Phase 3 | Unknown | Dr. Santiago Palacios | 50 | 2020-12-22 | 2021-06-02 |
| Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women vaginal estradiol 10 μg, vaginal DHEA 6.5 mg - Vulvovaginal Atrophy, Genitourinary Syndrome of Menopause | Phase 4 | Completed | Angelica Lindén Hirschberg | 170 | 2020-12-18 | 2024-12-17 |
| Photobiomodulation Effect on Vulvovaginal Atrophy in Postmenopausal Women. Estrogen vaginal cream group (group A), Photobiomodutation group (group B) - Vulvovaginal Atrophy | Phase 2 | Withdrawn | University of Nove de Julho | 2020-12-15 | 2023-06-29 | |
| Pilot Clinical Trial of IDRACARE® in Moderate to Severe Symptoms of Vulvovaginal Atrophy Idracare - Vulvovaginal Atrophy | Not applicable | Completed | Procare Health Iberia S.L. | 134 | 2020-10-26 | 2023-01-27 |
| A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women IVR Dose 1, IVR Dose 2, Oral Reference - Vulvovaginal Atrophy, Vasomotor Symptoms | Phase 1 | Completed | Daré Bioscience, Inc. | 34 | 2020-08-18 | 2024-10-15 |
| Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments Vulvovaginal Atrophy | Completed | Shionogi | 831 | 2020-07-07 | 2021-06-21 | |
| Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA WO533 - Vulvovaginal Atrophy | Phase 2 | Completed | Dr. August Wolff GmbH & Co. KG Arzneimittel | 43 | 2020-01-27 | 2021-12-23 |
| Efficacy and Safety of Hyaluronic Acid Injection on Symptoms of Vulvovaginal Atrophy in Postmenopausal Women Injection of DESIRIAL®, Injection of placebo - Vulvovaginal Atrophy | Not applicable | Completed | Laboratoires Vivacy | 121 | 2020-01-21 | 2023-04-10 |
| Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream Estradiol 10 MCG Vaginal Tablet [VAGIFEM], Promestriene Vaginal - Vulvovaginal Atrophy | Phase 3 | Completed | Instituto Palacios | 120 | 2020-01-09 | 2021-02-11 |
| Study to Evaluate Estradiol Vaginal Tablets vs Promestriene Vaginal Cream Estradiol - Vulvovaginal Atrophy | Completed | Instituto Palacios | 120 | 2019-12-09 | 2021-02-11 |
Showing 20 of 51. Sign in to see all of them.
Dyspareunia (12) · Breast Neoplasms (4) · Sexual Dysfunction, Physiological (3) · Atrophic Vaginitis (2) · Breast Carcinoma In Situ (1) · Dysuria (1) · Sexual Dysfunctions, Psychological (1) · Urinary Incontinence (1) · Urinary Incontinence, Stress (1) · Vulvodynia (1)
Genital Diseases (17) · Urogenital Diseases (17) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Genital Diseases, Female (14) · Male Urogenital Diseases (14) · Genital Diseases, Male (12) · Mental Disorders (12) · Sexual Dysfunction, Physiological (12) · Sexual Dysfunctions, Psychological (11) · Breast Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5)
Estradiol (4) · Dehydroepiandrosterone (3) · Vaginal Creams, Foams, and Jellies (3) · Estriol (2) · Estrogens (2) · Surveys and Questionnaires (2) · visnadin (2) · Control Groups (1) · Laser Therapy (1) · Lasers, Gas (1) · Ospemifene (1) · Oxytocin (1) · Petrolatum (1) · Probiotics (1) · Therapeutics (1)
Venus Concept (4) · Warner Chilcott (4) · Dr. August Wolff GmbH & Co. KG Arzneimittel (3) · Daré Bioscience, Inc. (2) · Fidia Farmaceutici s.p.a. (2) · Instituto Palacios (2) · TherapeuticsMD (2) · Angelica Lindén Hirschberg (1) · BTL Industries Ltd. (1) · Center for Vulvovaginal Disorders (1) · Centre Oscar Lambret (1) · Chulalongkorn University (1) · Dr. Santiago Palacios (1) · El. En. SpA (1) · Faculdade de Medicina do ABC (1)
United States (14) · Spain (6) · Canada (5) · Australia (4) · Belgium (4) · Germany (4) · Italy (3) · France (2) · Slovakia (2) · Sweden (2) · Brazil (1) · Israel (1) · Portugal (1) · Switzerland (1) · Thailand (1)
Anna Chan, PharmD (3) · Kirstin Deuble-Bente, MD (2) · Matthew Gronski, PhD (2) · Prof. Christoph Abels, MD, PhD (2) · Ahinoam Lev-Sagie, MD (1) · Aino Fianu Jonasson, MD (1) · Andreia A Antunes, PhD Student (1) · Antonia Pearson, BMed (1) · Becky K Lynn, MD (1) · David Friend, PhD (1) · Eric Sokol, MD (1) · Fernand Labrie, MD (1) · Fernando Losa, Doctor (1) · Gregor Reid, PhD (1)
PMID 37619252, PMID 12037029, PMID 15779109, PMID 24605832, PMID 25333211, PMID 28355090, PMID 29678557, PMID 30238814, PMID 31688572, PMID 34054104, PMID 34327510, PMID 34813408, PMID 36349391, PMID 36749915, PMID 36787527, PMID 37099983, PMID 37339390, PMID 37625088, PMID 38305601, PMID 40273666, PMID 40709601, PMID 40773978, PMID 41903372, PMID 42665344
2016 (2), 2019 (1)